The application relates to application of an iron
porphyrin compound in preparation of a tumor
metastasis inhibiting
drug and belongs to the technical field of biological medicines. The iron
porphyrin compound of the application inhibits tumor
metastasis through a triple
synergistic mechanism: first, the non-enzymatic
catalysis mode is used to improve the
intracellular NAD + level, the tumor
cell metabolism is changed from
glycolysis to
oxidative phosphorylation, and the tumor
cell metabolic flexibility is broken; second,
keratin and intermediate filament
protein overexpression is induced, the
cell skeleton mechanical rigidity is enhanced, and the tumor
cell deformation and migration are limited; and third, CD8 + T cells and M1 type macrophages are activated, the tissue immune surveillance is strengthened, the whole-chain
metastasis process of tumor dissociation, intravasation, circulation survival,
extravasation and
colonization is blocked from the source, and the tumor metastasis key link is comprehensively inhibited.